Pemphigus vulgaris is a rare autoimmune condition that causes painful blistering on the skin and mucous membranes. These blisters commonly appear in the mouth and are prone to bursting easily, which ...

PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

This is a rare autoimmune skin disorder that occurs when your immune system starts attacking healthy epidermis cells (the top layer of your skin). Pemphigus can manifest itself as blisters and sores ...

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Significantly ...

Cabaletta Bio, Inc. ((CABA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Rituxan met a primary endpoint and ...

PHILADELPHIA--(BUSINESS WIRE)--Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...

PHILADELPHIA--(BUSINESS WIRE)-- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...